obsolete alpha-thalassemia-abnormal morphogenesis
MONDO:0022425
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Alpha-thalassemia
Alpha-thalassemia (α-thalassemia, α-thalassaemia) is an inherited blood disorder and a form of thalassemia. Thalassemias are a group of inherited blood conditions which result in the impaired production of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, iron overload, abnormal bone structure, jaundice, and gallstones. In severe cases death ensues, often in infancy, or death of the unborn fetus. The disease is characterised by reduced production of the alpha-globin component of hemoglobin, caused by inherited mutations affecting the genes HBA1 and HBA2. This causes reduced levels of hemoglobin leading to anemia, while the accumulation of surplus beta-globin, the other structural component of hemoglobin, damages red blood cells and shortens their life. Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing. As an inherited condition, alpha thalassemia cannot be prevented although genetic counselling of parents prior to conception can propose the use of donor sperm or eggs. The principle form of management is blood transfusion every 3 to 4 weeks, which relieves the anemia but leads to iron overload and possible immune reaction. Medication includes folate supplementation, iron chelation, bisphosphonates, and removal of the spleen. Alpha thalassemia can also be treated by bone marrow transplant from a well matched donor. Thalass...
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.